SNGXW (Soligenix) EBIT per Share : $0.00 (TTM As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Soligenix EBIT per Share?

Soligenix's EBIT per Share for the three months ended in Sep. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

During the past 3 years, the average EBIT per Share Growth Rate was 53.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 32.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was 30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Soligenix's EBIT per Share or its related term are showing as below:

SNGXW' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -196.1 Med: 20.65 Max: 53.8
Current: 53.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Soligenix was 53.80% per year. The lowest was -196.10% per year. And the median was 20.65% per year.

SNGXW's 3-Year EBIT Growth Rate is ranked better than
94.64% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs SNGXW: 53.80

Soligenix's EBIT for the three months ended in Sep. 2024 was $-1.87 Mil.

Soligenix EBIT per Share Historical Data

The historical data trend for Soligenix's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix EBIT per Share Chart

Soligenix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

Soligenix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Soligenix EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Soligenix's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.859	/	0
=	N/A

Soligenix's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.865	/	0
=	N/A

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Soligenix (NAS:SNGXW) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Soligenix EBIT per Share Related Terms

Thank you for viewing the detailed overview of Soligenix's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGXW) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

SNGX:USA 0A6I:UK

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).